# Cagrilintide: What the Evidence Shows, and Why You Can't Buy It

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-10-04 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/cagrilintide-what-the-evidence-shows

> Cagrilintide, Novo Nordisk's amylin analog, produced 11.8% weight loss on its own at 68 weeks, less than semaglutide. It is not approved, cannot be compounded, and FDA has warned companies selling it.

Cagrilintide is an experimental once-weekly injection from Novo Nordisk that copies amylin, a fullness hormone the pancreas releases alongside insulin. It does work on its own: in the largest trial so far, people taking only cagrilintide lost 11.8% of their body weight over 68 weeks if they stayed on it, against 2.3% on placebo.[2] That is real weight loss, but less than semaglutide produced in the same trial. Cagrilintide is not approved anywhere, either alone or inside CagriSema, its combination with semaglutide. FDA says it cannot be used in compounding,[12] so there is no legal way to buy it. Our FDA warning-letter tracker holds 5 letters to companies that sold or supplied it.

> **About this article.** This page covers cagrilintide by itself: what it is, what it did when tested alone, where Novo is taking it, and why it cannot be sold. The combination with semaglutide has its own pages: [CagriSema against semaglutide in type 2 diabetes](https://glpwatchdog.org/research/cagrisema-superior-by-how-much) and [CagriSema against semaglutide alone in REDEFINE 5](https://glpwatchdog.org/research/more-effect-without-more-side-effects). Trial figures come from the published papers; where a number comes only from Novo Nordisk, we say so.

## What cagrilintide is

Amylin is a hormone made by the same pancreatic cells that make insulin, and it helps you feel full after eating.[1] The body’s own amylin is hard to turn into a drug because it tends to clump into fibrils. One older amylin drug, pramlintide, is sold for diabetes, but it wears off quickly and has to be injected three times a day.[6] Lilly and Zealand are now testing once-weekly amylin-only rivals, covered in [eloralintide and petrelintide](https://glpwatchdog.org/research/amylin-analogs-petrelintide-eloralintide).

Cagrilintide is Novo Nordisk’s answer to that problem: a stabilized amylin analog with a fatty-acid chain attached so it lasts long enough for one shot a week.[6] Novo describes it as working “differently than currently approved GLP-1-based treatments for weight loss.”[3] In mice, its weight-lowering effect depended on two specific amylin receptors in the brain,[7] which is consistent with the idea that it acts on appetite through a different route from semaglutide or tirzepatide. That difference is why Novo pairs the two drugs.

It is a separate approach from amycretin, which builds the GLP-1 and amylin actions into one molecule instead of combining two drugs. That trial is covered in [amycretin: what the phase 1b showed](https://glpwatchdog.org/research/amycretin-what-the-phase-1b-showed).

## Does cagrilintide work on its own?

Yes, but it is not as strong as semaglutide. The three randomized trials below report weight results for a cagrilintide-only group, and each found meaningful weight loss.

*Cagrilintide alone in published randomized trials. Weight change from baseline. The 2021 dose-finding figures assume everyone stayed on treatment.*

| Trial | Who and how long | Cagrilintide alone | Comparison groups |
| --- | --- | --- | --- |
| Phase 2 dose-finding (Lancet, 2021) | 706 adults (506 on cagrilintide), no diabetes, 26 weeks | −6.0% to −10.8%, by dose (0.3 to 4.5 mg) | Placebo −3.0%; liraglutide 3.0 mg −9.0% |
| Phase 2 in type 2 diabetes (Lancet, 2023) | 92 adults with type 2 diabetes, 32 weeks | Weight −8.1%; HbA1c −0.9 points | Semaglutide −5.1% and −1.8 points; CagriSema −15.6% and −2.2 points |
| REDEFINE 1, phase 3 (NEJM, 2025) | 3,417 adults, no diabetes, 68 weeks; 302 on cagrilintide 2.4 mg | −11.5% (everyone randomized); −11.8% (if on treatment) | Placebo −3.0% / −2.3%; semaglutide 2.4 mg −14.9% / −16.1% |

The first trial established the dose range. Every dose beat placebo, and the highest, 4.5 mg, edged out daily liraglutide by 1.8 percentage points at 26 weeks.[1] The diabetes trial was small, but it showed cagrilintide lowering blood sugar far less than semaglutide (0.9 points of HbA1c against 1.8), even though it lowered weight a little more over that short period.[4]

REDEFINE 1 is the one that matters most. It was built to test CagriSema, but it also randomized 302 people to cagrilintide 2.4 mg alone for 68 weeks. Counting everyone randomized, they lost 11.5% of their weight; if everyone had stayed on treatment, 11.8%. Semaglutide alone produced 14.9% and 16.1% on the same two measures.[2] Novo reports that about one in three people on cagrilintide (31.6%) lost at least 15% of their weight, against about one in twenty on placebo.[3] Few people on cagrilintide reached the very large losses: 6.5% lost a quarter of their weight or more, against 14.8% on semaglutide.[2]

Cagrilintide alone sits a little above liraglutide, an older daily GLP-1 drug, and well short of semaglutide or tirzepatide. Its case rests on what it adds in combination, and on how it feels to take.

## Side effects: the part that looks different

Like GLP-1 drugs, cagrilintide mainly causes stomach and gut side effects, plus injection-site reactions.[1] The difference is how often. In REDEFINE 1, gastrointestinal side effects were reported by 54.0% of people on cagrilintide, against 73.8% on semaglutide and 39.9% on placebo.[2]

*Safety in REDEFINE 1 at 68 weeks, from the published paper.*

| Measure | Cagrilintide 2.4 mg | Semaglutide 2.4 mg | Placebo |
| --- | --- | --- | --- |
| Gastrointestinal side effects | 54.0% | 73.8% | 39.9% |
| Stopped treatment because of side effects | 2.6% | 3.6% | 3.5% |
| Serious adverse events | 8.9% | 5.0% | 6.1% |

Fewer gut side effects and fewer people quitting over them is the strongest argument for cagrilintide alone. Novo reports that nausea made 1.0% of people on cagrilintide stop permanently, against 0.1% on placebo.[3] Serious adverse events were somewhat more common than on semaglutide. The trial was built to test CagriSema against placebo, not to compare the two single-drug groups, which held about 300 people each, so that gap should be read with care. In the 2023 diabetes trial, 80% of the cagrilintide group reported some adverse event, against 71% on semaglutide, in groups of about 30 people.[4] In REIMAGINE 2, 82.2% of the cagrilintide group reported one, against 70.5% on placebo.[5]

## Is Novo developing cagrilintide by itself?

Yes. After the REDEFINE 1 results, Novo said it would move cagrilintide into its own phase 3 program, called RENEW.[3] Two RENEW trials are registered.[8][9] Both compare once-weekly cagrilintide with placebo for 64 weeks, both started in November 2025, and both have finished enrolling. Results are expected in 2027.

*Cagrilintide-only phase 3 trials on ClinicalTrials.gov, October 2026.*

| Trial | Who | Planned size | Primary completion (estimated) |
| --- | --- | --- | --- |
| RENEW 1 (NCT07220642) | Adults with overweight or obesity | 300 | May 2027 |
| RENEW 2 (NCT07220759) | Adults carrying excess weight who also have type 2 diabetes | 330 | May 2027 |

Novo’s August 2026 financial report also lists a phase 3 trial of a higher cagrilintide dose as due to start in the fourth quarter of 2026.[11] Novo has not said when, or whether, it will file cagrilintide alone for approval, so there is no approval date to give.

## Is cagrilintide approved? The CagriSema decision

No. Cagrilintide is not approved on its own, and FDA states that it is not a component of any FDA-approved drug.[12] The first approval it could get is as part of CagriSema. The new drug application for CagriSema went in on December 18, 2025. Novo built it on two trials, REDEFINE 1 and REDEFINE 2, and said in the same announcement that CagriSema was approved in neither the US nor the EU.[10] Novo’s August 2026 report put the U.S. decision in the fourth quarter of 2026.[11] As of October 17, 2026, no decision had been announced.

An approval of CagriSema would not make cagrilintide on its own a legal prescription drug. It would approve one fixed combination product for weight management. How CagriSema compares with what is already on the market is on our [CagriSema vs Wegovy](https://glpwatchdog.org/compare/drugs/cagrisema-vs-wegovy) and [CagriSema vs Zepbound](https://glpwatchdog.org/compare/drugs/cagrisema-vs-zepbound) pages, and the full late-stage field is on the [GLP-1 pipeline tracker](https://glpwatchdog.org/glp1-pipeline).

## Can you buy cagrilintide?

Not legally. FDA puts it plainly:

> Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.[12]
>
> — FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss

With no approved product and no compounding route, there is no lawful source for a patient. Our explainer on [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded) sets out the rules, and [are peptides legal?](https://glpwatchdog.org/research/are-peptides-legal) covers the wider peptide market.

It is sold anyway, mostly as a powder in a vial from “research peptide” websites. FDA has rejected that label in its letters. One seller marketed “CAGRILINTIDE” and a cagrilintide–semaglutide blend called “CagriLean” while labeling them “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE”; FDA found the products were intended as drugs for people.[13] Another seller’s cagrilintide page borrowed trial-style claims, such as weight loss of 25% or more in 40.4% of patients, while its labels said “laboratory research purposes only.”[14] Others hide it behind code names: one letter records a “Cag (1mg) Tirz (10mg) Blend,” mixing cagrilintide with tirzepatide.[16]

FDA has also reached the supply chain behind compounders. It warned an ingredient distributor that had imported and sold cagrilintide; the company told FDA it had stopped importing and distributing it, and FDA accepted that correction.[15] None of these products went through the trials above. A vial labeled cagrilintide is not the drug Novo tested, and there is no way for a buyer to check what is in it.

## The FDA warning letters that name cagrilintide

Our [FDA warning-letter tracker](https://glpwatchdog.org/fda-warning-letters) holds 5 letters that name cagrilintide, dated December 2024 through March 2026. Several of the same letters also name retatrutide, which is covered in [retatrutide: what the evidence shows](https://glpwatchdog.org/research/retatrutide-what-the-evidence-shows).

*FDA warning letters naming cagrilintide in our tracker. Each links to our summary of the letter.*

| What the letter describes | Letters | Companies (letter date) |
| --- | --- | --- |
| Sold as a “research” peptide, with a research-use label FDA rejected | 3 | [Xcel Research](https://glpwatchdog.org/fda-warning-letters/xcel-research-llc-694608) (Dec. 10, 2024), [Summit Research Peptides](https://glpwatchdog.org/fda-warning-letters/summit-research-peptides-695607) (Dec. 10, 2024), [Prime Sciences](https://glpwatchdog.org/fda-warning-letters/prime-sciences-721805) (March 31, 2026) |
| Sold in a cagrilintide–tirzepatide blend under a code name | 1 | [PekCura Labs](https://glpwatchdog.org/fda-warning-letters/pekcura-labs-721709) (March 31, 2026) |
| Ingredient distributor that imported and sold cagrilintide | 1 | [Darmerica](https://glpwatchdog.org/fda-warning-letters/darmerica-llc-716152) (Dec. 8, 2025) |

## What to do instead

- **Use an approved drug.** Semaglutide (Wegovy) and tirzepatide (Zepbound) are [approved for weight management](https://glpwatchdog.org/research/best-injection-for-weight-loss). In REDEFINE 1, semaglutide alone produced more weight loss than cagrilintide alone.[2]
- **Join a trial if you want cagrilintide itself.** Inside a registered study is the only way to take it legally. The RENEW trials have finished enrolling,[8] but ClinicalTrials.gov lists several smaller cagrilintide studies that are still recruiting.
- **Wait for the CagriSema decision.** If FDA approves it, that will be the first legal way to get cagrilintide outside a trial, and only as part of the combination.[11]

> **If you have already used cagrilintide from an online seller,** tell your doctor what you took and keep the packaging. FDA asks patients and clinicians to report side effects or quality problems to its MedWatch program.[12]

## Frequently asked questions

### What is cagrilintide?

Cagrilintide is an experimental once-weekly injection from Novo Nordisk that mimics amylin, a fullness hormone released by the pancreas along with insulin. It acts on appetite through a different route from GLP-1 drugs such as semaglutide, and it is the second ingredient in CagriSema.

### Does cagrilintide work for weight loss on its own?

Yes, though less than semaglutide. In the 68-week REDEFINE 1 trial, people on cagrilintide 2.4 mg alone lost 11.8% of their body weight if they stayed on treatment, against 16.1% on semaglutide 2.4 mg and 2.3% on placebo. It caused fewer gastrointestinal side effects than semaglutide in that trial.

### Is cagrilintide FDA approved?

No. Cagrilintide is not approved anywhere, alone or in combination. Novo Nordisk filed CagriSema, which pairs it with semaglutide, with FDA in December 2025 and has said it expects a U.S. decision in the fourth quarter of 2026; none had been announced as of October 17, 2026. Cagrilintide alone is in phase 3 trials with results expected in 2027.

### Can I buy cagrilintide legally?

No. Under federal law, FDA says, cagrilintide may not be compounded, and it is not part of any approved drug. Products sold online as research peptides are not legal to sell for human use, and FDA has sent warning letters to companies selling them.

### Is cagrilintide the same as CagriSema?

No. Cagrilintide is one drug. CagriSema is a fixed combination of cagrilintide 2.4 mg and semaglutide 2.4 mg in one weekly injection. In REDEFINE 1, CagriSema produced more weight loss than either drug alone.

### What are the side effects of cagrilintide?

Mostly gastrointestinal effects such as nausea, constipation and diarrhea, plus injection-site reactions. In REDEFINE 1, 54.0% of people on cagrilintide reported gastrointestinal side effects, against 73.8% on semaglutide and 39.9% on placebo, and 2.6% stopped because of side effects.

## References

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021. PMID: 34798060. DOI: 10.1016/S0140-6736(21)01751-7. https://pubmed.ncbi.nlm.nih.gov/34798060/
2. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025. PMID: 40544433. DOI: 10.1056/NEJMoa2502081. https://pubmed.ncbi.nlm.nih.gov/40544433/
3. Novo Nordisk A/S Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme (company-reported). Company announcement, September 16, 2025. 2025. https://www.nasdaq.com/press-release/novo-nordisk-presents-phase-3-data-next-generation-amylin-cagrilintide-leading
4. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 2023. PMID: 37364590. DOI: 10.1016/S0140-6736(23)01163-7. https://pubmed.ncbi.nlm.nih.gov/37364590/
5. Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The Lancet Diabetes & Endocrinology. 2026. PMID: 42251859. DOI: 10.1016/S2213-8587(26)00125-7. https://pubmed.ncbi.nlm.nih.gov/42251859/
6. Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021. PMID: 34288673. DOI: 10.1021/acs.jmedchem.1c00565. https://pubmed.ncbi.nlm.nih.gov/34288673/
7. Carvas AO, Leuthardt A, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025. PMID: 40609154. DOI: 10.1016/j.ebiom.2025.105836. https://pubmed.ncbi.nlm.nih.gov/40609154/
8. U.S. National Library of Medicine Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity (RENEW 1), NCT07220642. ClinicalTrials.gov, accessed October 4, 2026. 2026. https://clinicaltrials.gov/study/NCT07220642
9. U.S. National Library of Medicine Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes (RENEW 2), NCT07220759. ClinicalTrials.gov, accessed October 4, 2026. 2026. https://clinicaltrials.gov/study/NCT07220759
10. Novo Nordisk Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. PR Newswire, December 18, 2025. 2025. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
11. Novo Nordisk A/S Financial report for the period 1 January 2026 to 30 June 2026 (Form 6-K). U.S. Securities and Exchange Commission, August 2026. 2026. https://www.sec.gov/Archives/edgar/data/0000353278/000035327826000023/caq22026.htm
12. U.S. Food and Drug Administration FDA's concerns with unapproved GLP-1 drugs used for weight loss. FDA, content current as of October 1, 2026. 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
13. U.S. Food and Drug Administration Warning letter: Xcel Research LLC, MARCS-CMS 694608. FDA, December 10, 2024. 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024
14. U.S. Food and Drug Administration Warning letter: Prime Sciences, MARCS-CMS 721805. FDA, March 31, 2026. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026
15. U.S. Food and Drug Administration Warning letter: Darmerica, LLC, MARCS-CMS 716152. FDA, December 8, 2025. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025
16. U.S. Food and Drug Administration Warning letter: PekCura Labs, MARCS-CMS 721709. FDA, March 31, 2026. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026

---

Cite as: GLP Watchdog, Ruth Calder, "Cagrilintide: What the Evidence Shows, and Why You Can't Buy It", published 2026-10-04, updated 2026-10-27. https://glpwatchdog.org/research/cagrilintide-what-the-evidence-shows

Canonical HTML page: https://glpwatchdog.org/research/cagrilintide-what-the-evidence-shows

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
